Ajanta Pharma Complete Financial Statements
12 Years of Data
2026 - 2015
In FY2026, Ajanta Pharma (AJANTPHARM) reported revenue ₹1,483 Cr, net profit ₹267 Cr and EPS ₹21.35, with a net profit margin of 18.0% and ROE of 7.0%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore Ajanta Pharma intrinsic price to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Net Profit Margin
18.00%
2026 data
EBITDA Margin
26.64%
2026 data
Operating Margin
23.00%
2026 data
Return on Assets
5.32%
2026 data
Return on Equity
7.04%
2026 data
Balance Sheet Ratios
Current Ratio
12.41
2026 data
Equity Ratio
75.57%
2026 data
Asset Turnover
0.30
2026 data
AJANTPHARM Revenue, Net Profit & EBITDA — Year-on-Year Growth
AJANTPHARM YoY (Mar 2025 vs Mar 2026) — revenue +24.7%, net profit +18.7%, EBITDA +25.4%, expenses +24.6%. For live price, earnings ratios and company overview, see Ajanta Pharma share price today.
Revenue Growth
+24.7%
Year-over-Year
Net Profit Growth
+18.7%
Year-over-Year
EBITDA Growth
+25.4%
Year-over-Year
Expense Growth
+24.6%
Year-over-Year
Assets Growth
+8.1%
Year-over-Year
Equity Growth
+6.3%
Year-over-Year
Operating Cash Flow Growth
+47.4%
Year-over-Year
Investing Cash Flow Growth
-680.0%
Year-over-Year
Financing Cash Flow Growth
+30.3%
Year-over-Year
AJANTPHARM Income Statement — Revenue, EBITDA & Net Profit
Ajanta Pharma revenue ₹1,483 Cr, EBITDA ₹395 Cr, net profit ₹267 Cr, EPS ₹21.35 (2026) — net profit margin 18.0%. Review AJANTPHARM earnings valuation to evaluate earnings-based valuation against sector peers.
Periods
₹ Crores
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Mar 2016 | Jun 2016 | Dec 2016 | Sept 2015 | Mar 2015 | Jun 2015 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,483 | 1,413 | 1,189 | 1,329 | 1,400 | 1,206 | 1,090 | 1,171 | 1,177 | 1,050 | 919 | 1,053 | 1,119 | 978 | 900 | 984 | 1,007 | 914 | 759 | 781 | 862 | 721 | 739 | 681 | 754 | 656 | 517 | 620 | 666 | 559 | 536 | 519 | 490 | 550 | 483 | 478 | 602 | 523 | 429 | 481 | 552 | 445 | 369 | 394 | 472 |
| Expenses | 1,088 | 1,026 | 873 | 951 | 993 | 876 | 776 | 815 | 825 | 738 | 733 | 750 | 791 | 742 | 664 | 729 | 802 | 622 | 497 | 528 | 598 | 442 | 533 | 445 | 507 | 466 | 388 | 444 | 466 | 378 | 391 | 354 | 378 | 357 | 319 | 346 | 390 | 343 | 289 | 310 | 356 | 288 | 248 | 269 | 313 |
| EBITDA | 395 | 387 | 315 | 378 | 407 | 331 | 314 | 357 | 351 | 312 | 186 | 303 | 328 | 237 | 236 | 255 | 205 | 292 | 262 | 253 | 264 | 279 | 206 | 236 | 247 | 190 | 129 | 176 | 200 | 182 | 145 | 166 | 112 | 193 | 163 | 132 | 213 | 179 | 140 | 171 | 197 | 157 | 121 | 125 | 159 |
| Operating Profit Margin % | 23.00% | 24.00% | 25.00% | 27.00% | 28.00% | 26.00% | 26.00% | 29.00% | 28.00% | 28.00% | 17.00% | 27.00% | 28.00% | 21.00% | 24.00% | 23.00% | 17.00% | 30.00% | 34.00% | 29.00% | 29.00% | 38.00% | 22.00% | 33.00% | 32.00% | 27.00% | 25.00% | 28.00% | 29.00% | 31.00% | 26.00% | 31.00% | 22.00% | 34.00% | 33.00% | 27.00% | 34.00% | 33.00% | 32.00% | 35.00% | 33.00% | 34.00% | 32.00% | 30.00% | 33.00% |
| Depreciation | 45 | 43 | 40 | 41 | 44 | 34 | 34 | 34 | 36 | 34 | 33 | 33 | 34 | 33 | 31 | 32 | 33 | 32 | 31 | 31 | 32 | 28 | 26 | 28 | 29 | 23 | 19 | 23 | 24 | 18 | 17 | 17 | 19 | 15 | 19 | 13 | 15 | 14 | 11 | 13 | 15 | 11 | 13 | 10 | 12 |
| Interest | 2 | 3 | 6 | 5 | 5 | 6 | 2 | 1 | 8 | 2 | 1 | 1 | 3 | 1 | 7 | 1 | 3 | 0 | 3 | 2 | 1 | 2 | 4 | 2 | 3 | 5 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 |
| Profit Before Tax | 347 | 341 | 269 | 331 | 359 | 290 | 278 | 322 | 307 | 276 | 152 | 269 | 291 | 203 | 198 | 222 | 168 | 260 | 229 | 220 | 231 | 249 | 176 | 207 | 216 | 162 | 109 | 151 | 175 | 164 | 128 | 148 | 93 | 178 | 144 | 119 | 198 | 165 | 134 | 158 | 181 | 148 | 115 | 119 | 153 |
| Tax | 80 | 81 | 44 | 76 | 85 | 74 | 75 | 76 | 75 | 81 | 30 | 61 | 81 | 46 | 47 | 47 | 34 | 65 | 70 | 47 | 39 | 79 | 47 | 59 | 39 | 45 | 20 | 37 | 68 | 38 | 34 | 43 | 26 | 46 | 30 | 24 | 50 | 35 | 25 | 39 | 38 | 45 | 41 | 33 | 39 |
| Net Profit | 267 | 260 | 225 | 255 | 274 | 217 | 203 | 246 | 233 | 195 | 122 | 208 | 210 | 157 | 151 | 175 | 135 | 196 | 159 | 174 | 192 | 170 | 129 | 148 | 177 | 116 | 89 | 115 | 108 | 125 | 95 | 106 | 67 | 132 | 114 | 95 | 148 | 131 | 109 | 120 | 143 | 103 | 74 | 86 | 114 |
| Earnings Per Share (₹) | 21.35 | 20.83 | 18.00 | 20.44 | 21.91 | 17.27 | 16.10 | 19.54 | 18.60 | 15.51 | 9.54 | 16.53 | 16.68 | 12.22 | 17.70 | 13.63 | 10.50 | 15.10 | 18.40 | 20.08 | 22.16 | 19.51 | 14.80 | 16.93 | 20.41 | 13.34 | 10.10 | 13.14 | 12.33 | 14.25 | 10.74 | 12.02 | 7.60 | 14.99 | 12.96 | 10.77 | 16.76 | 14.85 | 12.38 | 13.58 | 16.19 | 11.76 | 8.43 | 9.78 | 12.95 |
AJANTPHARM Balance Sheet — Assets, Liabilities & Shareholders' Equity
AJANTPHARM total assets ₹5,015 Cr, total equity ₹3,790 Cr, total liabilities ₹ Cr (2025) — ROE 7.0%.
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 5,015 | 4,638 | 4,679 | 4,056 | 3,779 | 3,319 | 2,696 | 2,449 | 1,848 | 1,481 | 1,146 |
| Current Assets | 2,843 | 2,731 | 2,834 | 2,265 | 2,028 | 1,642 | 1,180 | 1,224 | 851 | 764 | 633 |
| Fixed Assets | 1,762 | 1,479 | 1,496 | 1,512 | 1,541 | 1,472 | 1,178 | 1,053 | 589 | 452 | 288 |
| Capital Work in Progress | 176 | 257 | 210 | 153 | 108 | 132 | 262 | 61 | 339 | 240 | 170 |
| Investments | 464 | 349 | 535 | 147 | 176 | 79 | 78 | 190 | 182 | 66 | 20 |
| Other Assets | 2,613 | 2,554 | 2,438 | 2,244 | 1,954 | 1,635 | 1,179 | 1,145 | 738 | 724 | 669 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 229 | 175 | 152 | 144 | 135 | 114 | 73 | 61 | 33 | 38 | 56 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 3,790 | 3,567 | 3,388 | 3,264 | 2,996 | 2,599 | 2,245 | 2,041 | 1,568 | 1,172 | 841 |
| Share Capital | 25 | 25 | 25 | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves & Surplus | 3,765 | 3,542 | 3,363 | 3,247 | 2,978 | 2,581 | 2,228 | 2,024 | 1,550 | 1,154 | 823 |
AJANTPHARM Cash Flow Statement — Operating, Investing & Financing
Ajanta Pharma operating cash flow ₹1,157 Cr, investing ₹-377 Cr, financing ₹-733 Cr, net cash flow ₹47 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,157 | 785 | 792 | 562 | 576 | 457 | 375 | 281 | 609 | 326 | 279 |
| Investing Activities | -377 | 65 | -560 | -74 | -282 | -224 | -223 | -256 | -383 | -209 | -158 |
| Financing Activities | -733 | -1,051 | -108 | -460 | -318 | -129 | -148 | 0 | -202 | -117 | -105 |
| Net Cash Flow | 47 | -201 | 124 | 28 | -24 | 104 | 4 | 25 | 24 | 0 | 16 |